This study intends to explore the predictive biomarkers by Next-generation sequencing (NGS) and multiple immunohistochemistry (mIHC) for the treatment of SHR1210 in combination with paclitaxel and platinum in advanced esophageal cancer.
|Condition||Advanced Esophageal Cancer|
|Treatment||SHR-1210 + paclitaxel + cisplatin|
|Clinical Study Identifier||NCT05174156|
|Sponsor||Sixth Affiliated Hospital, Sun Yat-sen University|
|Last Modified on||6 January 2022|
You have contacted , on
Your message has been sent to the study team at ,
You are contacting
No annotations made yet
Congrats! You have your own personal workspace now.